7 Major Coronavirus Developments — RI’s EpiVax to Raise $1.75M for Clinical Trial for Vaccine

GoLocalProv News Team

7 Major Coronavirus Developments — RI’s EpiVax to Raise $1.75M for Clinical Trial for Vaccine

Anne De Groot, EpiVax
Rhode Island’s EpiVax, Inc., announced it is using advanced computational tools to accelerate a COVID-19 vaccine candidate (EPV-CoV19) for healthcare workers (HCW) and is pushing to get this into clinical trials in 6 months.

EpiVax has been one of Rhode Island's star biotech firms.

GET THE LATEST BREAKING NEWS HERE -- SIGN UP FOR GOLOCAL FREE DAILY EBLAST

According to EpiVax, EPV-CoV19 is a peptide-based, epitope-driven vaccine that can be rapidly and safely produced in most countries.

Once the company has raised $1.75 million the company will enter clinical trials -- the company has pledged to make a free license available to developing countries if the vaccine is successful. 

To raise the funds EpiVax has partnered with GAIA Vaccine Foundation (“GVF”) to crowd-source funds.

MAKE A DONATION HERE

EpiVax seeking to raise $1.75M
Annie De Groot, MD, EpiVax CEO/CSO, states “The soul of each company will be revealed during this crisis. Personally, I do not believe this is the time to become a billionaire. Each of us should do what we do best to reduce the impact of COVID-19 globally.”

WATCH: Former RI Director of Health Dr. Michael Fine on GoLocal LIVE at 12 PM on Wednesday

"Applying EpiVax’s expertise enabled the selection of sequences representing all circulating SARS-CoV-2 genomes that will drive a T cell-mediated immune response, providing HCW with immune system “body armor”, reducing their risk of morbidity and mortality,” said the company.

GVF, a 501(c)(3) nonprofit organization, will enable private citizens and foundations to contribute to development of EPV-CoV19. GVF’s mission is to reduce incidence of infectious diseases that disproportionately affect the under-served and promote the development of globally relevant, accessible vaccines that can be distributed on a not-for-profit basis in the developing world.

As it is the mission of EpiVax to “improve human health everywhere”, the company has granted GVF a cost-free, royalty-free license to the EPV-CoV19 design for use in countries that can produce and test the vaccine candidate on the Least Developed Countries list published by the United Nations. Collaborators and a clinical trial site in West Africa have been identified.

READ 7 Major Coronavirus Developments BELOW


7 Major Coronavirus Developments — Wednesday, April 8, 2020

Enjoy this post? Share it with others.